Encoded to drive first gene therapy into clinic with GV-led $135M series D

With plans to begin human testing of its Dravet syndrome therapy in early 2021, Encoded has raised $135 million in an untranched series D round led by GV that will also fund a natural history study to inform

Read the full 381 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE